Patient-Derived Xenograft (PDX) Models
Patient-derived xenograft (PDX) models have gained significant recognition as a robust tool in cancer research, providing a more faithful representation of human tumors. At our company, a renowned pioneer in PDX model development, we offer a comprehensive range of services to support the scientific community. Our services encompass the establishment, customization, characterization, and preclinical testing of PDX models, as well as collaboration opportunities with esteemed partners.
Overview of PDX Models
Patient-derived xenograft (PDX) models are generated by engrafting tumor tissue obtained from cancer patients into immunodeficient mice. These models faithfully mirror the key attributes of the original tumor, encompassing its heterogeneity, molecular characteristics, and microenvironment. In contrast to conventional cell lines or genetically engineered mouse models (GEMMs), PDX models offer a superior reflection of human cancers. The advantages of PDX models are as follows:
- There is currently no available in vitro cultivation process for tumor screening.
- Preserve the inherent characteristics and heterogeneity of the tumor.
- Maintain the tumor's molecular biology at a consistent level.
- Retain the original non-tumor stroma and microenvironment.
- Enable the study of patient-derived tumors under various conditions.
Fig.1 Schematic diagram of the establishment of PDX. (Liu, Yihan, et al., 2023)PDX Model for Rare Cancers
In 1918, Yamagiwa and Ichikawa successfully created the first cancer model. Subsequently, in 1951, the first cell line was established, which played a significant role in advancing cancer science. The introduction of CDX models further contributed to scientific advancements related to cancer research. Moreover, PDX models were introduced in 1969 followed by GEMMs (Genetically Engineered Mouse Models) in 1981. The following table enumerates the applications of PDX models in rare cancers.
Table 1 PDX models in rare cancers. (Liu, Yihan, et al., 2023)
| Cancer type | PDX type | Objective | Trial design | Current status |
|---|---|---|---|---|
| Head and neck squamous cell carcinoma (HNSCC) | − | Generate a biobank of PDX representing the different subgroups of HNSCC. | Create a dataset consisting of primary and recurrent tumor tissues for PDX establishment. Conduct research to identify new biomarkers, novel therapeutic approaches, and mechanisms of drug resistance. | Recruiting |
| Colorectal cancer, High-grade serous ovarian cancer, TNBC | − | Evaluate the utility of PDX as a predictor to direct the use of chemo- and targeted therapies. | Molecular profiling and in vivo drug testing should be conducted on patient-derived xenograft (PDX) models and organoid cultures. | Recruiting |
| Pancreatic cancer | Mini-PDX | Provide precision diagnosis and therapeutics for different stages of cancer patients. | Generate Mini-PDX and conduct RNA sequencing and drug sensitivity tests to identify the most effective medicine. | Recruiting |
| Urogenital cancer | Chick embryos | Test PDX efficiency and guide individualized therapeutics. | Administer specific medications to PDX and assess the efficacy of each drug. | Completed |
Our Services
With our unique understanding of each rare disease research project, our company provides customized PDX model development services to meet specific research needs. Our company offers drug safety evaluation and pharmacokinetics research using PDX models to evaluate the effectiveness of various therapeutic interventions. Our expertise in PDX model-based preclinical testing enables researchers to make informed decisions in advancing their therapeutic candidates.
Sample Collection
We work closely with cancer centers and hospitals to obtain tumor tissue from patients and ensure its successful engraftment into immunodeficient mice. Our experienced team meticulously handles the entire process, from tissue collection and processing to model characterization.
Sample Transplantation
Conventional PDX models are often created using immunocompromised mice to avoid rejection of tumor implants. Commonly used transplantation methods include subcutaneous transplantation and xenotransplantation. The transplantation process is sterile, accurate and efficient.
Post-transplant Observations
Following transplantation, meticulous monitoring of tumor growth and development was conducted, with regular measurements of tumor volume. When the tumor reached a size range of 800-1200mm3, tumor tissue was carefully excised and dissected into small fragments for subsequent passages and maintenance.
Model Validation
Our company employs a comprehensive set of techniques to validate PDX models, including histopathological analysis, genomic profiling, and functional assays. By thoroughly characterizing the PDX models, we ensure their fidelity to the original patient tumor and provide researchers with reliable and representative models for their studies.
Why Choose Us?
As a leading company dedicated to researching and developing therapies for rare diseases, we pride ourselves on offering our esteemed clients a cost-effective and convenient solution. Our comprehensive service revolves around the development of patient-derived xenograft (PDX) models, which optimizes workflow efficiency. Our dedicated team of extensively trained scientists leverages our cutting-edge platform to deliver exceptional services and produce customized, high-quality products that cater to the specific needs of each customer. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Liu, Yihan, et al. "Patient-derived xenograft models in cancer therapy: Technologies and applications." Signal Transduction and Targeted Therapy 8.1 (2023): 160.
- Abdolahi, Shahrokh, et al. "Patient-derived xenograft (PDX) models, applications and challenges in cancer research." Journal of Translational Medicine 20.1 (2022): 206.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.